FDA Approves New Adjuvant Therapy for High-Risk Kidney Cancer Patients
A new adjuvant treatment for clear cell renal cell carcinoma (ccRCC) recently received FDA approval, offering hope for patients at high risk of recurrence.
A new adjuvant treatment for clear cell renal cell carcinoma (ccRCC) recently received FDA approval, offering hope for patients at high risk of recurrence.